9780896032231 - IVIG Therapy Today (Allergy and Immunology, 2, Band 2) von Ballow, Mark (7 Ergebnisse)

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: Used. pp. 164 68:B&W 7 x 10 in or 254 x 178 mm Case Laminate on White w/Gloss Lam.

Zustand: Used. pp. 164.

Zustand: New. In.

Gebunden. Zustand: New. It has been little more than a century since Emil von Behring and his colleagues (1890) showed that the blood of tetanus-immune rabbits contained a factor that could be transferred to nonimmune animals to protect them against tetanus. These observations, to.

Zustand: New. Presents reviews of primary and acquired humoral/B-cell immune deficiencies, featuring IVIG as replacement therapy, and explores the immunomodulatory effects of IVIG in autoimmune disorders. This title covers background information and clinical applications, including IVIG replacement therapy in primary immune deficiency syndrome. Series: Allergy and Immunology. Num Pages: 157 pages, biography. BIC Classification: MMG. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 254 x 178 x 11. Weight in Grams: 507. . 1992. Hardback. . . . . Books ship from the US and Ireland.

Buch. Zustand: Neu. Neuware - It has been little more than a century since Emil von Behring and his colleagues (1890) showed that the blood of tetanus-immune rabbits contained a factor that could be transferred to nonimmune animals to protect them against tetanus. These observations, together with the work of Paul Ehrlich, started scientists on the long and complex path to our present understanding of the humoral, or B-cell, immune system. These early studies led to Nobel prize awards for von Behring (1901 ) and Ehrlich (1908), each of whom contributed much to our knowledge of the B-cell immune system. In the early 20th century it was recognized that the serum of individuals who had recently suffered an infection contained a protective humoral factor that could be transferred to a nonimmune person, thereafter affording that individual protection against the infectious agent that had caused disease. In 1933 McKhann and Chu reported that a placental extract containing the globulin fraction could modify measles. However, it was not until 1939 that Tiselius and Kabat demonstrated that the antibodies responsible for protection against these infectious disorders resided within the gammaglobulin plasma fraction. In a major step forward, Cohn in 1944 established a method for the fractionation and purification of this plasma gammaglobulin fraction. These procedures, which are based on cold ethanol precipitation of plasma, produce a readily adaptable, large-scale fractionation procedure that is still utilized to this day in the preparation of commercial gammaglobulin.